Age related macular degeneration

The late stage manifestations of age related macular degeneration, neovascularisation and geographic atrophy, cause severe loss of central vision Standard care for neovascular age related macular degeneration is treatment with monoclonal antibodies that inhibit vascular endothelial growth factor.A fifth of those treated do not respond to treatment and a further quarter may lose the initial gains in visual acuity over time.No proven treatments exist for geographic atrophy.The preventive effects of supplementation with macular carotenoids (lutein/zeaxanthin) and omega3 fatty acids are under investigation.Age related macular degeneration, as the term implies, affects older adults and accounts for about half of all vision impairment or blind